Malignant peripheral nerve sheath tumor pathophysiology: Difference between revisions
Shanshan Cen (talk | contribs) |
Shanshan Cen (talk | contribs) |
||
Line 7: | Line 7: | ||
===Genetics=== | ===Genetics=== | ||
About half of the cases of malignant peripheral nerve sheath tumor (MPNST) occur along with [[NF1]], which is a genetic mutation on the 17th chromosome that causes tumors along the nervous system. The lifetime risk of having both of these conditions is at 8–13% while those with only MPNST have a 0.001% in the general population.<ref>{{cite journal|last=Ferrari|first=Andrea|author2=Gianni Bisogno |author3=Modesto Carli |title=Management Of Childhood Malignant Peripheral Nerve Sheath Tumor | journal=Pediatric Drugs | date=2007|volume=9|issue=4|pages=239–48|accessdate=5 Mar 2014 | pmid=17705563 | doi=10.2165/00148581-200709040-00005}}</ref> | |||
==Pathogenesis== | ==Pathogenesis== |
Revision as of 14:03, 2 December 2015
Malignant peripheral nerve sheath tumor Microchapters |
Differentiating Malignant Peripheral Nerve Sheath Tumor from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Malignant peripheral nerve sheath tumor pathophysiology On the Web |
American Roentgen Ray Society Images of Malignant peripheral nerve sheath tumor pathophysiology |
FDA on Malignant peripheral nerve sheath tumor pathophysiology |
CDC on Malignant peripheral nerve sheath tumor pathophysiology |
Malignant peripheral nerve sheath tumor pathophysiology in the news |
Blogs on Malignant peripheral nerve sheath tumor pathophysiology |
Directions to Hospitals Treating Malignant peripheral nerve sheath tumor |
Risk calculators and risk factors for Malignant peripheral nerve sheath tumor pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Overview
Causes
Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.
Genetics
About half of the cases of malignant peripheral nerve sheath tumor (MPNST) occur along with NF1, which is a genetic mutation on the 17th chromosome that causes tumors along the nervous system. The lifetime risk of having both of these conditions is at 8–13% while those with only MPNST have a 0.001% in the general population.[1]
Pathogenesis
Malignant peripheral nerve sheath tumors are a rare type of cancer that arise from the soft tissue that surrounds nerves. They are a type of sarcoma. Most malignant peripheral nerve sheath tumors arise from the nerve plexuses that distribute nerves into the limbs—the brachial and lumbar plexuses—or from nerves as they arise from the trunk.[2]
References
- ↑ Ferrari, Andrea; Gianni Bisogno; Modesto Carli (2007). "Management Of Childhood Malignant Peripheral Nerve Sheath Tumor". Pediatric Drugs. 9 (4): 239–48. doi:10.2165/00148581-200709040-00005. PMID 17705563.
|access-date=
requires|url=
(help) - ↑ Panigrahi, S.; Mishra, S.; Das, S.; Dhir, M. (2013). "Primary malignant peripheral nerve sheath tumor at unusual location". Journal of Neurosciences in Rural Practice. 4 (5): 83. doi:10.4103/0976-3147.116480. PMC 3808069. PMID 24174807.